[甲状腺乳头状癌中BRAF突变的研究及其临床价值]
[An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
作者信息
Gong Ri-xiang, Zhou Yang, Luo Shu-hua, Zhang Lin, Zhou Bin
机构信息
Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041 PR China.
出版信息
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009 Jun;26(3):310-3. doi: 10.3760/cma.j.issn.1003-9406.2009.03.016.
OBJECTIVE
To study the relationship between BRAF mutation and clinicopathological features in papillary thyroid carcinoma (PTC).
METHODS
Fresh samples were examined for the presence of BRAF mutations in 43 patients with PTC and 20 patients with non-PTC thyroid disease and 40 normal thyroid tissues by polymerase chain reaction (PCR) and direct sequencing. The relationship between BRAF mutation and clinicopathological features was studied.
RESULTS
BRAF mutation was detected in 39.5% (17/43) of PTC samples, in 0 of non-PTC thyroid disease samples and normal thyroid tissues. Significant association was seen between BRAF mutation and both extrathyroidal invasion and cervical lymph node metastasis (P<0.05, P<0.05). There was no significant relationship between BRAF mutation and gender, age at the time of diagnosis, tumor size and distant metastasis.
CONCLUSION
BRAF mutation is associated with extrathyroidal invasion and lymph node metastasis. It may increase the ability of invasion and metastasis of PTC and have influence on prognosis.
目的
研究甲状腺乳头状癌（PTC）中BRAF突变与临床病理特征之间的关系。
方法
采用聚合酶链反应（PCR）和直接测序法，检测43例PTC患者、20例非PTC甲状腺疾病患者的新鲜样本以及40例正常甲状腺组织中BRAF突变情况。研究BRAF突变与临床病理特征之间的关系。
结果
在43例PTC样本中，39.5%（17/43）检测到BRAF突变，非PTC甲状腺疾病样本和正常甲状腺组织中未检测到BRAF突变。BRAF突变与甲状腺外侵犯和颈部淋巴结转移均显著相关（P<0.05，P<0.05）。BRAF突变与性别、诊断时年龄、肿瘤大小及远处转移之间无显著关系。
结论
BRAF突变与甲状腺外侵犯和淋巴结转移相关。它可能增加PTC的侵袭和转移能力，并对预后产生影响。
Zotero 插件